Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 07/31/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. PCVX, MRUS, CYTK, RNA, ADMA, KRYS, MTSR, ABVX, ZLAB, and AKROShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Vaxcyte (PCVX), Merus (MRUS), Cytokinetics (CYTK), Avidity Biosciences (RNA), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Metsera (MTSR), Abivax (ABVX), Zai Lab (ZLAB), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Its Competitors Vaxcyte Merus Cytokinetics Avidity Biosciences ADMA Biologics Krystal Biotech Metsera Abivax Zai Lab Akero Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends. Do institutionals & insiders believe in CALT or PCVX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is CALT or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Vaxcyte's return on equity of -17.12% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Vaxcyte N/A -17.12%-16.26% Which has more risk & volatility, CALT or PCVX? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Which has higher valuation and earnings, CALT or PCVX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Vaxcyte. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62VaxcyteN/AN/A-$463.93M-$3.99-8.28 Does the media favor CALT or PCVX? In the previous week, Vaxcyte had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Vaxcyte and 0 mentions for Calliditas Therapeutics AB (publ). Vaxcyte's average media sentiment score of 1.34 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Vaxcyte Positive Do analysts recommend CALT or PCVX? Vaxcyte has a consensus target price of $136.50, indicating a potential upside of 313.39%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 SummaryVaxcyte beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$763.52M$5.48B$9.51BDividend YieldN/A4.84%4.73%4.09%P/E Ratio-21.621.3428.6723.80Price / Sales0.7425.20373.9066.58Price / CashN/A19.5635.4557.96Price / Book37.746.778.275.55Net Income-$43.96M-$4.28M$3.24B$259.03M7 Day PerformanceN/A-4.26%-3.69%-4.59%1 Month PerformanceN/A0.54%4.33%4.46%1 Year Performance3.49%15.94%25.95%18.03% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180PCVXVaxcyte2.2389 of 5 stars$35.87-2.1%$136.50+280.5%-58.0%$4.73BN/A-8.99160News CoveragePositive NewsUpcoming EarningsMRUSMerus2.9208 of 5 stars$65.59-1.8%$86.40+31.7%+25.1%$4.62B$36.13M-16.0837News CoverageCYTKCytokinetics4.0154 of 5 stars$36.63-1.5%$70.92+93.6%-36.6%$4.44B$19.22M-6.92250News CoverageUpcoming EarningsAnalyst ForecastInsider TradeRNAAvidity Biosciences2.7815 of 5 stars$34.56-4.7%$66.35+92.0%-19.4%$4.37B$10.90M-11.52190News CoverageUpcoming EarningsADMAADMA Biologics4.2926 of 5 stars$18.00-0.1%$27.67+53.7%+57.7%$4.30B$426.45M21.18530Upcoming EarningsKRYSKrystal Biotech4.8885 of 5 stars$152.91+3.6%$211.33+38.2%-21.0%$4.27B$290.52M36.76210Upcoming EarningsMTSRMetseraN/A$39.43-2.6%$55.00+39.5%N/A$4.25BN/A0.0081News CoverageEarnings ReportLockup ExpirationAnalyst RevisionGap UpABVXAbivax3.6107 of 5 stars$66.57+0.1%$85.33+28.2%+511.7%$4.22BN/A0.0061News CoverageAnalyst ForecastGap DownZLABZai Lab2.217 of 5 stars$38.69+4.1%$54.28+40.3%+99.7%$4.13B$398.99M-15.541,869News CoveragePositive NewsUpcoming EarningsShort Interest ↑Gap UpAKROAkero Therapeutics3.9641 of 5 stars$49.24-2.6%$82.50+67.5%+83.6%$4.03BN/A-25.2530Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Vaxcyte Alternatives Merus Alternatives Cytokinetics Alternatives Avidity Biosciences Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives Metsera Alternatives Abivax Alternatives Zai Lab Alternatives Akero Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
